Glybuzole

Glybuzole

SCHEMBL34401

CC(C)(C)c1nnc(NS(=O)(=O)c2ccccc2)s1

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.71
MAPT P10636 1/20 0.71
HPGD P15428 1/20 0.71
TSHR P16473 1/20 0.71
HSD17B10 Q99714 1/20 0.71
CYP2C9 P11712 1/20 0.67
CYP2C19 P33261 1/20 0.67
PKM P14618 2/20 0.66
AKT1 P31749 1/20 0.62
ATM Q13315 1/20 0.61
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58
CA5A P35218 2/20 0.58
CA5B Q9Y2D0 2/20 0.58
CA12 O43570 1/20 0.58
CA3 P07451 1/20 0.58
CA6 P23280 1/20 0.58
CA7 P43166 1/20 0.58
CA9 Q16790 1/20 0.58
CA14 Q9ULX7 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30978753 0.85 MEN1 (0.75) ALDH1A1MAPTHPGDTSHRHSD17B10
Glybuthiazol SCHEMBL282607 0.85 ALDH1A1 (0.71) ALDH1A1MAPTHPGDTSHRHSD17B10
SCHEMBL5404442 0.85 ALDH1A1 (0.71) ALDH1A1MAPTHPGDTSHRHSD17B10
SCHEMBL5394860 0.85 MEN1 (0.74) ALDH1A1MAPTHPGDTSHRHSD17B10
SCHEMBL5401782 0.84 ALDH1A1 (0.65) ALDH1A1MAPTHPGDTSHRHSD17B10
SCHEMBL30578971 0.83 ALDH1A1 (1.00) ALDH1A1MAPTHPGDTSHRHSD17B10
SCHEMBL286763 0.80 ALDH1A1 (1.00) ALDH1A1MAPTHPGDTSHRHSD17B10
SCHEMBL1094305 0.80 ALDH1A1 (0.72) ALDH1A1HPGDPKMAKT1ATM
SCHEMBL5392537 0.78 ALDH1A1 (1.00) ALDH1A1MAPTHPGDHSD17B10PKM
SCHEMBL15884465 0.78 CA1 (0.65) ALDH1A1PKMATMCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2553 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022164850-A1 COMPOUNDS TO PREVENT OR TREAT SARS-CoV-2 VARIANT INFECTION UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2022-08-04 WO claimed
US-20180118773-A1 CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR THERACOSBIO, LLC 2018-05-03 US claimed
US-9517273-B2 Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids AMBRX, INC. (US) 2016-12-13 US claimed
US-9179994-B2 Implantable film/mesh composite COVIDIEN LP (US) 2015-11-10 US claimed
US-20150273075-A1 THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES COMPRISING NON-NATURALLY OCCURRING AMINO ACIDS AMBRX, INC. 2015-10-01 US claimed
US-9005308-B2 Implantable film/mesh composite for passage of tissue therebetween COVIDIEN LP (US) 2015-04-14 US claimed
US-20150051289-A1 LIQUID FORMULATIONS OF HYPOGLYCAEMIC SULFONAMIDES AMMTEK (FR) 2015-02-19 US claimed
US-8932621-B2 Implantable film/mesh composite COVIDIEN LP (US) 2015-01-13 US claimed
EP-2819679-A1 LIQUID FORMULATIONS OF HYPOGLYCAEMIC SULPHONAMIDES Ammtek (FR) 2015-01-07 EP claimed
US-20140142520-A1 IMPLANTABLE DEVICES INCLUDING A MESH AND A PIVOTABLE FILM COVIDIEN LP (US) 2014-05-22 US claimed
US-20030104066-A1 Easy-to-take granules KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-06-05 US claimed
EP-1303304-A2 PHARMACEUTICAL COMBINATIONS FOR TREATMENT AND PREVENTION OF DIABETES MELLITUS Keri Pharma KFT (HU) 2003-04-23 EP claimed
WO-2003007951-A1 A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR TREATMENT OF DIABETES N-GENE RESEARCH LABORATORIES INC. (US) 2003-01-30 WO claimed
EP-1269995-A1 EASY-TO-TAKE GRANULE KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-01-02 EP claimed
WO-2002005795-A2 PHARMACEUTICAL COMBINATIONS FOR TREATMENT AND PREVENTION OF DIABETES MELLITUS Kéri Pharma Kft. (HU) 2002-01-24 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
CN-1156403-A Highly active sulphonyl urea preparations exhibiting rapid or controlled release of the active substance, and method of producing them BRITISH TECHNOLOGY GROUP CO LT (GB) 1997-08-06 CN claimed